2160 Share Price Performance
Recent 2160 News & Updates
No updates
MicroPort CardioFlow Medtech Corporation Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.02
- Gross Margin
- 69.48%
- Net Profit Margin
- -13.68%
- Debt/Equity Ratio
- 1.9%
MicroPort CardioFlow Medtech Corporation Competitors
About 2160
- Founded
- 2009
- Employees
- 430
- CEO
- WebsiteView website
MicroPort CardioFlow Medtech Corporation, a medical device company, engages in the research, development, and commercialization of transcatheter and surgical solutions for structural heart diseases in the People’s Republic of China and internationally. The company engages in research and development, manufacture, and sale of medical devices in the field of left atrial appendage, and treating valvular heart diseases, as well as properties management. It’s product portfolio includes transcatheter aortic valves, left atrial appendage closure, transcatheter mitral valves, transcatheter tricuspid valves, and surgical accessories, as well as procedural accessories; and VitaFlow, VitaFlow Liberty, VitaFlow Liberty Flex, Alwide Plus, AccuSniperTM, AnchorMan LAAC System, AnchorMan LAAA System, and various TAVI, TMV, TTV, and LAA products. In addition, the company provides technical consultation and technical services for medical devices clinical trial. MicroPort CardioFlow Medtech Corporation was founded in 2009 and is headquartered in Shanghai, China.
Chinese Market Performance
- 7 Days: -1.1%
- 3 Months: 10.9%
- 1 Year: 30.1%
- Year to Date: 11.3%
Over the last 7 days, the market has dropped 1.1%, driven by a loss of 1.9% in the Industrials sector. As for the longer term, the market has actually risen by 30% in the last year. Looking forward, earnings are forecast to grow by 24% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading